Medicare drug spending will slow due to IRA price negotiations, CMS...
Medicare spending on prescription drugs is expected to grow at a slower rate between 2028 and 2033 as a result of drug pricing provisions in the Inflation Reduction Act, a report by members of CMS' ...
View ArticleEndpoints Livestream: ACIP and the future of vaccines
Today on Post-Hoc Live, I'll be joined by senior editor Zachary Brennan and pharma reporter Max Bayer for a wide-ranging discussion about the remade Advisory Committee on Immunization Practices and how...
View ArticleNovartis strikes cardiovascular discovery deal with Flagship’s ProFound
Novartis has signed up proteomics specialist ProFound Therapeutics to pinpoint “previously unknown” proteins to be investigated as cardiovascular drugs and drug targets in a $25 million upfront deal....
View ArticleVor Bio bounces back with RemeGen autoimmune deal, $175M private placement
In an unexpected turn of events, Vor Bio is back on the fundraising trail and shifting focus to autoimmune disease, less than two months after it seemed to be at the end ...
View ArticleBharat, GSK to cut malaria vaccine price; Emergent's US stockpile deal expands
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bharat Biotech and GSK said they will reduce the price of their ...
View ArticleHandspring Health raises $12M to provide more complex care for youth
Youth virtual mental health startup Handspring Health just raised $12 million, Endpoints News has learned exclusively. Cobalt Ventures led the Series A round, with contributions from NextView Ventures,...
View ArticleWhy Commure, one of healthcare's most deal-hungry startups, plans to buy more...
Commure, one of the buzziest healthcare startups backed by General Catalyst, is hunting for more startups to buy — AI scribes included. Commure has been on a shopping spree over the past few years,...
View ArticleOpus, Viatris say presbyopia drug succeeds in Phase 3
Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year. The phentolamine ophthalmic solution 0.75% program ...
View ArticleEdgewise details pivotal plans in Becker muscular dystrophy; Kymera’s $250M...
Plus, news about Hummingbird, Percheron, Pfizer and I-Mab: Edgewise Therapeutics can’t get accelerated approval for muscle disease drug: The biotech said the FDA deemed its Phase 2 CANYON data...
View ArticleAltimmune posts mixed results for incretin drug in MASH; stock is halved
Altimmune said its experimental therapy for a serious fatty liver disease hit one key endpoint but not the other in a Phase 2b study. The biotech’s shares {$ALT} tanked after the ...
View Article